XML 36 R25.htm IDEA: XBRL DOCUMENT v3.25.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2025
shares
Trading Arrangements, by Individual  
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
John C.M. Farquhar [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement On September 12, 2025, John C.M. Farquhar, our President and Chief Executive Officer, adopted a Rule
10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 427,900
shares of our common stock. The duration of the trading arrangement is until January 11, 2027, or earlier
if all transactions under the trading arrangement are completed. The trading arrangement is intended to
satisfy the affirmative defense in Rule 10b5-1(c).
Name John C.M. Farquhar
Title President and Chief Executive Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date September 12, 2025
Expiration Date January 11, 2027
Arrangement Duration 486 days
Aggregate Available 427,900
Campbell D.K. Rogers [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement On September 12, 2025, Campbell D.K. Rogers, M.D., our Chief Medical Officer, adopted a Rule 10b5-1
trading arrangement providing for the sale from time to time of an aggregate of up to 254,144 shares of
our common stock. The duration of the trading arrangement is until April 2, 2026, or earlier if all
transactions under the trading arrangement are completed. The trading arrangement is intended to satisfy
the affirmative defense in Rule 10b5-1(c).
Name Campbell D.K. Rogers
Title Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date September 12, 2025
Expiration Date April 2, 2026
Arrangement Duration 202 days
Aggregate Available 254,144
Julie A. Cullivan [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement On September 12, 2025, Julie A. Cullivan, one of our directors, adopted a Rule 10b5-1 trading
arrangement providing for the sale from time to time of an aggregate of up to 17,122 shares of our
common stock. The duration of the trading arrangement is until March 27, 2026, or earlier if all
transactions under the trading arrangement are completed. The trading arrangement is intended to satisfy
the affirmative defense in Rule 10b5-1(c).
Name Julie A. Cullivan
Title directors
Rule 10b5-1 Arrangement Adopted true
Adoption Date September 12, 2025
Expiration Date March 27, 2026
Arrangement Duration 196 days
Aggregate Available 17,122